600 patients66,869 observations120 daysLIVE

Patient P-01674

Synthetic patientNBL-101 · Day 110 · 65–74 · M · baseline S14Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Deteriorating
GI state
Improving
Inflammatory state
Stable
Nutritional resilience
Stable
Discontinuation risk
57%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S14
  2. Day 48 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 51 GI-04 recommendedGI Support Protocol GI-04
  4. Day 52 Patient acceptedStarted GI-04 in the companion
  5. Day 54 SC-12 recommendedSupportive Compound SC-12
  6. Day 55 Patient acceptedStarted SC-12 in the companion
  7. Day 60 GI symptom burden −32% vs expectedGI Support Protocol GI-04
  8. Day 61 No meaningful changeSupportive Compound SC-12
  9. Day 66 Tolerance state changedUnstable → Improving
  10. Day 70 ME-01 recommendedMonitoring Escalation ME-01
  11. Day 71 Patient acceptedStarted ME-01 in the companion
  12. Day 74 Deterioration detected before clinical escalationMonitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 48.

Primary contributors, last 14 days
  • Toxicity+8
  • GI instability-7
  • Treatment adherence+5
  • Inflammatory activity-2

What helped?

  • GI Support Protocol GI-04Day 51
    Result: symptom burden −32%
  • Supportive Compound SC-12Day 54
    Result: no meaningful change
  • Monitoring Escalation ME-01Day 70
    Result: deterioration detected before clinical escalation
LIFE OS recommendation
Dietary Support Protocol NP-02
52%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 68% showed improvement
  • median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden
Companion
39.7/100
improving · -6.4 vs previous 14 d
Toxicity
Blood
45.7/100
worsening · +12.3 vs previous 14 d
Sleep quality
Wearable
42.5/100
improving · +5.8 vs previous 14 d
Energy level
Daily log
4.4/10
stable · -0.1 vs previous 14 d
Stress level
Daily log
5.5/10
stable · +0.2 vs previous 14 d
Steps
Wearable
5,268
improving · +259 vs previous 14 d
Adherence
Companion
55.7 %
stable · -0.5 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards restoration · 42 from the failing basin, 45 from restoration.

Would help
  • NP-02 Dietary Support Protocol
    63% improved among 63 similar · onset 10 d · confidence 59%
  • CR-01 Clinician Review
    100% improved among 7 similar · onset 5 d · confidence 59%
Would not help
  • SC-12 Supportive Compound
    already tried, no meaningful change
  • Keep fat low
    GI +5.8 next day on high-intake days · n 20
  • Keep simple carbs low
    GI +5 next day on high-intake days · n 11
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Dietary fat load
    +5.8detractor · 95%
  • Simple carbohydrates
    +5detractor · 93%
  • Histamine load
    -1.6no signal · 34%
  • Spicy / capsaicin
    -0.7no signal · 17%
  • Insoluble fibre
    +0.6no signal · 15%
  • Alcohol
    -0.5no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Inflammatory signalling 85
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 47
    • WearableHRV 35 ms, trending down
  • Butyrate / short-chain fatty acid production 60
    • MicrobiomeButyrate capacity 25/100
    • MicrobiomeF. prausnitzii depleted
  • Mucosal barrier integrity 30
    • MicrobiomeAkkermansia low → thinner mucus layer
  • Drug metabolism and exposure 20
    • BloodToxicity index 46
DNA
Fictional pharmacogenomic panel
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Normal metabolizer
    Expected exposure
  • MTHFR C677T
    Reduced folate turnover
Microbiome
Shannon diversity 2.5 · butyrate capacity 25/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumLow
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
37 ms
Sleep
7.1 h
Steps
3,296
Resting HR
64 bpm
Daily log: GI score 40, nutritional resilience 50, adherence 56.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Keep meals regular; three to four moderate portions spaced through the day
  • Include a cooked vegetable portion with each main meal
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Log the daily check-in; one line is enough
  • Keep the current walking rhythm
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • No additional supplements this week
  • Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0168840%S01GI-04improved40
P-0132739%S01GI-04improved56
P-0131029%S0157
P-0181329%S01NP-02no change40
P-0182127%S0158
P-0182327%S0157
P-0184626%S0137
P-0145525%S01GI-04improved61
P-0163542%S02GI-04improved49
P-0145234%S02GI-04improved46
P-0145930%S0251
P-0149927%S0265